Cleminorexton

Cleminorexton
Clinical data
Other namesORX750; ORX-750
Routes of
administration
Oral
Drug classOrexin receptor agonist; Orexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
  • 1-fluoro-N-[(16S,17S)-4,6,23-trifluoro-11-oxo-8-oxa-12-azatetracyclo[17.3.1.02,7.012,17]tricosa-1(22),2(7),3,5,19(23),20-hexaen-16-yl]cyclopropane-1-sulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H24F4N2O4S
Molar mass512.52 g·mol−1
3D model (JSmol)
  • C1C[C@@H]([C@@H]2CC3=C(C(=CC=C3)C4=C(C(=CC(=C4)F)F)OCCC(=O)N2C1)F)NS(=O)(=O)C5(CC5)F
  • InChI=1S/C24H24F4N2O4S/c25-15-12-17-16-4-1-3-14(22(16)27)11-20-19(29-35(32,33)24(28)7-8-24)5-2-9-30(20)21(31)6-10-34-23(17)18(26)13-15/h1,3-4,12-13,19-20,29H,2,5-11H2/t19-,20-/m0/s1
  • Key:XGXKCWFIUAZZRS-PMACEKPBSA-N

Cleminorexton (INNTooltip International Nonproprietary Name; former developmental code name ORX750) is an orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.

See also